Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease
Nirosen Vijiaratnam, Thomas Foltynie
Drugs (2020) Vol. 80, Iss. 8, pp. 775-796
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Parkinson’s disease: etiopathogenesis and treatment
Joseph Jankovic, Eng King Tan
Journal of Neurology Neurosurgery & Psychiatry (2020) Vol. 91, Iss. 8, pp. 795-808
Open Access | Times Cited: 785
Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets
Komal Thapa, Heena Khan, Thakur Gurjeet Singh, et al.
Journal of Molecular Neuroscience (2021) Vol. 71, Iss. 9, pp. 1725-1742
Closed Access | Times Cited: 213
New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs)
Chella Perumal Palanisamy, Jinjin Pei, Phaniendra Alugoju, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4138-4165
Open Access | Times Cited: 66
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
BMJ Open (2021) Vol. 11, Iss. 5, pp. e047993-e047993
Open Access | Times Cited: 60
Closing the loop for patients with Parkinson disease: where are we?
Hazhir Teymourian, Farshad Tehrani, Katherine Longardner, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 8, pp. 497-507
Closed Access | Times Cited: 50
Deep brain stimulation in PD: risk of complications, morbidity, and hospitalizations: a systematic review
Markey Olson, Holly A. Shill, Francisco A. Ponce, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 15
Targeting phosphodiesterase 4 as a potential therapy for Parkinson’s disease: a review
Pooja Devi Nongthombam, Reena Haobam
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 4
Recent Advances in Rotigotine Nanoformulations for Parkinson’s Disease Therapy
Sanchit Arora, Dalapathi Gugulothu
BioNanoScience (2025) Vol. 15, Iss. 2
Closed Access
Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
Amnon A. Berger, Ariel Winnick, Alexandra Welschmeyer, et al.
Neurology International (2020) Vol. 12, Iss. 3, pp. 109-129
Open Access | Times Cited: 32
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
Daniel G. Di Luca, Nikolai Gil D. Reyes, Susan H. Fox
Drugs (2022) Vol. 82, Iss. 10, pp. 1027-1053
Open Access | Times Cited: 18
Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs
Nbaa Masood, Joohi Jimenez‐Shahed
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 247-266
Open Access | Times Cited: 9
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease
Wolfgang H. Jost, Jaime Kulisevsky, Peter A. LeWitt
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 821-826
Closed Access | Times Cited: 9
Cerium oxide nanoparticles modulating the Parkinson's disease conditions: From the alpha synuclein structural point of view and antioxidant properties of cerium oxide nanoparticles
Xiaomei Yao, Yichao Guan, Jianli Wang, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e21789-e21789
Open Access | Times Cited: 9
Opicapone: A Review in Parkinson’s Disease
Lesley J. Scott
CNS Drugs (2021) Vol. 35, Iss. 1, pp. 121-131
Closed Access | Times Cited: 21
Tratamiento farmacológico de los síntomas motores de la enfermedad de Parkinson: actualización y recomendaciones de un experto
Jaime Kulisevsky
Revista de Neurología (2022) Vol. 75, Iss. S04, pp. S1-S1
Open Access | Times Cited: 14
l -Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson’s disease
Khadga Raj, Ghanshyam Das Gupta, Shamsher Singh
Drug and Chemical Toxicology (2021) Vol. 45, Iss. 5, pp. 2097-2108
Closed Access | Times Cited: 17
Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's disease
К. Ray Chaudhuri, Annette Hand, Fallon Obam, et al.
Journal of Medical Economics (2022) Vol. 25, Iss. 1, pp. 774-782
Open Access | Times Cited: 12
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
Silvia Rota, Daniele Urso, Daniel J. van Wamelen, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 9
The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability
Christine Girges, Nirosen Vijiaratnam, Dilan Athauda, et al.
Drugs & Aging (2021) Vol. 38, Iss. 5, pp. 355-373
Open Access | Times Cited: 12
Patient Preferences for Treating “OFF” Episodes in Parkinson’s Disease: A Discrete Choice Experiment
Andrew Thach, Jessie Sutphin, Joshua Coulter, et al.
Patient Preference and Adherence (2021) Vol. Volume 15, pp. 1187-1196
Open Access | Times Cited: 9
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials
Yoshio Tsuboi, Masatoshi Nakamura, Hidenori Maruyama, et al.
Journal of the Neurological Sciences (2021) Vol. 430, pp. 120026-120026
Open Access | Times Cited: 9
Zonisamide’s Efficacy and Safety on Parkinson’s Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review
Linghui Kong, Jiaqiu Xi, Zhenyuan Jiang, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-17
Open Access | Times Cited: 6
Revisiting the assessment of tremor: clinical review
Nirosen Vijiaratnam, Thomas Wirth, Huw R. Morris
British Journal of General Practice (2020) Vol. 70, Iss. 701, pp. 611-614
Open Access | Times Cited: 4
Istradefylline Safety Profiles: Examination of Individual Case Safety Reports in the FDA Adverse Event Reporting System (FAERS) Database
WU Wen-hua, Haoxin Liang, Zhengrui Chen, et al.
Research Square (Research Square) (2024)
Open Access
Prescribing medications for Parkinson's: part two
Gina Robinson
Journal of Prescribing Practice (2024) Vol. 6, Iss. 4, pp. 166-172
Closed Access
Page 1 - Next Page

Scroll to top